15. International EBHC Symposium 2020

From Evidence to Action
5-7 października 2020 | ONLINE

15. International EBHC Symposium 2020
From Evidence to Action
5-7 października 2020 | ONLINE
Małgorzata Bała
Małgorzata Bała
Marcin Czech
Marcin Czech
Aleksandra Czerw
Aleksandra Czerw
Hans-Peter Dauben
Hans-Peter Dauben
Joanna Didkowska
Joanna Didkowska
Dominik Dziurda
Dominik Dziurda
Krzysztof Giannopoulos
Krzysztof Giannopoulos
Roman Kolek
Roman Kolek
Mariusz Kordecki
Mariusz Kordecki
Dorota Korycińska
Dorota Korycińska
Katarzyna Kotulska-Jóźwiak
Katarzyna Kotulska-Jóźwiak
Oskar Kowalski
Oskar Kowalski
Maciej Krawczyk
Maciej Krawczyk
Brygida Kwiatkowska
Brygida Kwiatkowska
Maria Libura
Maria Libura
Line Helen Linstad
Line Helen Linstad
Adam Maciejczyk
Adam Maciejczyk
Maciej Niewada
Maciej Niewada
James O’Brien
James O’Brien
Maria Piętak-Frączek
Maria
Piętak-Frączek
Robert Plisko
Robert Plisko
Tomasz Jan Prycel
Tomasz Jan Prycel
Przemysław Ryś
Przemysław Ryś
Holger Schünemann
Holger Schünemann
Tomasz Tatara
Tomasz Tatara
Victoria Thomas
Victoria Thomas
Roman Topór-Mądry
Roman Topór-Mądry
Magdalena Władysiuk
Magdalena Władysiuk
Marek Wójcik
Marek Wójcik

top

Ze względu na zagrożenie COVID-19 i niepewną sytuację epidemiczną na całym świecie, w 2020 roku po raz pierwszy w historii nasze Sympozjum odbyło się wyłącznie online. Program 15. Sympozjum EBHC został zrealizowany w ciągu 3 dni w ramach sześciu sesji tematycznych:

  1. Assessing innovativeness of health technologies
  2. HTA and new types of health technologies
  3. Health policy, drug policy – from strategy to implementation
  4. Who is responsible for the patient in the healthcare system?
  5. Local government academy
  6. From data to big data

Od założenia Stowarzyszenia CEESTAHC w 2003 roku jego członkowie stworzyli setki opracowań: analiz, rekomendacji, wytycznych i raportów. Teoretycznie wypracowaliśmy i udostępniliśmy społeczeństwu tysiące stron przydatnej wiedzy, która może poprawić efektywność działania systemu ochrony zdrowia w Polsce. Tyle, że praktycznie zaledwie ułamek tej wiedzy znalazł zastosowanie w realnych działaniach, mających na celu poprawę sytuacji. Z naszych doświadczeń wynika, że jakikolwiek przełożenie na rzeczywistość mają opracowania zaadoptowane na potrzeby prostych działań wykonywanych na niższych szczeblach organizacji systemu ochrony zdrowia (np. programów zdrowotnych).

The remaining knowledge exists and expands thanks to new primary studies; it is also repeatedly processed in subsequent secondary studies. However, an average participant of the system is not aware of the existence and scale of new information which is constantly becoming available. The ever growing collection of data (Evidence) is like a mycelium which covers an entire forest – it remains virtually invisible and the desired effects spring up like mushrooms only in specific places and conditions. These external manifestations of that mycelium’s life are our Actions undertaken within the healthcare system: health programmes, system reforms, implementation of solutions. Only ideas which face favourable circumstances have a chance to succeed. The question is, is this how it is supposed to be?

Over the course of several years of working on solution optimisation, we have learned that the hardest stage of implementing any innovation within a large system is putting ideas into action. Transferring results of analyses and solution proposals to decision makers and then to the people who will be implementing them requires no less effort than the entire process of research and analysis. Insufficient effort put into promoting specific solutions, lack of ideas on how to communicate or poor communication can delay practical application of scientific work for many years, if not ruin the chance of putting an innovation to use altogether.

Transitioning from the research and analytical stage to implementation is difficult because it is associated with several serious obstacles:

  • Zmiana środowiska. Wypielęgnowany pomysł opuszcza inkubator i swoich naukowych rodziców by trafić pod opiekę ludzi, którzy mogą na co dzień zajmować się zupełnie innymi zagadnieniami i dla których pomysł może być niezrozumiały.
  • Lęk przed zmianą. O ile w procesie twórczym autorzy pomysłu widzą w nim same korzyści, to potencjalni wykonawcy mogą skupić się na tym co z ich stabilnego środowiska pracy zostanie zaburzone lub utracone w wyniku wdrożenia nowego rozwiązania.
  • Sceptycyzm. Po tylu latach wypróbowywania w Polsce różnych nietrafionych, często szytych pod polityczne zapotrzebowania, rozwiązań, interesariusze rynku zdrowia mogą być nieufni wobec kolejnych „wspaniałych i jedynych słusznych usprawnień”.
  • Uwarunkowania polityczne. Ochrona zdrowia jest tematem delikatnym i ze względu na nieustanny wpływ na życie wszystkich obywateli wrażliwym na histeryczne reakcje. Stąd u decydentów może występować dodatkowy opór przed zmianami, które niosą ze sobą ryzyko naruszenia istniejącego status quo. Cykl wyborczy też może być przekleństwem dla reform, bo wszelkie rozwiązania wymagające przystosowywania przez czas dłuższy niż kadencja wyborcza jest zagrożony skasowaniem przy ewentualnej zmianie władzy, często zanim zdąży zacząć działać.
  • Brak pomysłu na wdrożenie. Większość budżetów projektów badawczych nie przewiduje a priori środków na przekucie przyszłych owoców badań na programy wdrożeniowe innowacji. Zaczynając projekt, dąży się do uzyskania środków na same badania. Praca badawcza ma to do siebie, że udowadnia lub obala hipotezy, więc często trudno jest na początku zakładać praktyczne wykorzystanie wyników, bo są one jeszcze nieznane. Gdy w wyniku analizy powstanie pomysł na usprawnienie, to działania tracą rozpęd z powodu braku planu działania i środków.

Ostatnie miesiące zmagań z COVID-19 wymusiły na ludzkości natychmiastowe przejście do Action, aby stawić czoła zagrożeniu nieopisanemu jeszcze w Evidence. Zaistniała sytuacja potwierdza słuszność kierunku wyznaczonego przez temat Sympozjum: from Evidence to Action. Musimy wypracować narzędzia do szybszego wdrażania wiedzy, żeby na przyszłość nie dać się już zaskoczyć na tak szeroką i czasami tragiczną skalę.
Podejrzewamy, że trudności z przejściem od Evidence do Action to nie tylko polski problem. Zapewne tysiące badaczy na całym świecie odczuwają na jakimś etapie kariery zawodowej niesatysfakcjonujący wpływ swoich wysiłków na poprawę sytuacji w rzeczywistym świecie. Czołowe światowe organizacje, takie jak Cochrane Collaboration, od lat publikują streszczenia swoich raportów napisane przystępnym językiem, udostępniane w językach narodowych (tzw. plain language summary, PLS). Mają one na celu dzielenie się wiedzą z osobami nieobeznanymi z naukową nomenklaturą i bez biegłej znajomości angielskiego. Jest to próba udzielenia dostępu do grzybni (Evidence) z pominięciem czekania na owocniki (Action). Naszym pomysłem na popularyzację wiedzy są rysunkowe streszczenia wykładów wygłoszonych w ramach 15. Sympozjum EBHC. Zapraszamy do galerii.

15. International EBHC Symposium 2020 From Evidence to Action
5-7 października 2021 | ONLINE
15. International EBHC Symposium 2020
From Evidence to Action
5-7 października 2020 | ONLINE

Session 1: Assessing innovativeness of health technologies

Defining and assessing innovation has been of strategic importance in healthcare for quite some time, both for drugs and medical devices, as well as for new types of technologies in the area of m-health or big data. While the term “innovation” implies some enhanced qualities/benefits, there is still little consensus as to what true innovation represents. In recent years, different countries have been working hard on the concept of innovation and methods of defining and assessing new health technologies. Not every health technology is innovative and not every health technology is innovative enough. The discussion on assessment focuses on the criteria and innovation levels. Since 2007, pharmaceutical companies in Italy have been able to apply for innovation status for their drugs to facilitate their access to reimbursement. On 6 April 2017, the Italian Medicines Agency (AIFA) published a new algorithm to help characterise and define recognised therapeutic innovations. Similar solutions have been tested as part of the Cancer Plan in the UK or the Netherlands or, recently, as part of the Medical Fund project in Poland. Related solutions for non-drug technologies are under development. The new algorithm is characterised by multi-dimensional approaches, including solutions based on the GRADE methodology or the concept of MCDA. As part of this session, we want to present solutions adopted by various countries, and discuss their practical implications for the healthcare system.
Sesja 1. Ocena innowacyjności technologii medycznych. Rys. Maciej Dziadyk maciejdziadyk.pl

top

Session 2: HTA and new types of health technologies

Health Technology Assessment (HTA) refers to systematic assessment of new health technologies in terms of health, economic, legal and many other effects. The main objective of this assessment is to inform decision makers about its findings and support them in the decision-making process. However, as new types of technologies are introduced, HTA also faces new methodological and analytical challenges. On the one hand, we want to introduce new technologies, on the other hand, a need to give up or reduce the usage of the existing technologies arises. The development of implantable medical devices, particularly new digital healthcare solutions, such as mobile services (m-health or e-health), artificial intelligence (AI) and robotics, have brought about great potential for the further development of healthcare services, but their introduction should follow the same criteria as other healthcare services. It seems that, despite lack of high-quality evidence, many of them may offer health benefits, however, the issue of everyday safety and their impact on the health or life of patients requires further observation and analysis. In many countries, efforts have been made to create a new HTA framework and develop legislation related to their financing within in guaranteed benefit packages. France, Spain, Germany and Scandinavian countries regulate the scope of the assessment of these technologies at various levels, along with detailed assessments of changes in the functioning of not only service providers or the system, but primarily taking into account their impact on clinical aspects – using similar assessment methodology as for other technologies. In cooperation with professionals from different countries, we wish to present the key aspects of changes in comprehensive HTA in various health areas and for various types of health technologies.
Sesja 2. HTA a nowe typy technologii medycznych. Rys. Maciej Dziadyk maciejdziadyk.pl
top

Session 3: Health policy, drug policy – from strategy to implementation

A state's health policy, including drug policy, refers to decisions, plans and actions undertaken to achieve specific health goals in the society. Health policy as an action strategy aims to define several aspects, such as the vision of the future, which in turn helps to set goals and benchmarks in the short and medium term. The creation of these solutions in social communication is supposed to respond to the growing challenges faced by the healthcare system, including monitoring and extending universal access, taking action in the field of public health and strengthening health in all areas of the state's activity. Documents such as the Health Policy also refer to social determinants of health and interactions between the health sector and other sectors of the society. The scope of state activity indicated in such documents indicates what actions take priority and what are the expectations regarding the scope of changes in the system. It should also be emphasised that they are usually created by multidisciplinary teams. As part of this session, we want to present the challenges faced by oncology, medical devices, rehabilitation, chronic care and other areas. This will be the first session in the history of the EBHC Symposium to cover entire healthcare areas, both in Poland and worldwide.
Sesja 3. Polityka zdrowotna, polityka lekowa – od strategii do wdrożenia. Rys. Maciej Dziadyk maciejdziadyk.pl
top

Session 4: Who is responsible for the patient in the healthcare system?

Since the 1980s, the role of patients in healthcare systems has become more prominent at various levels; they became involved not only in their own care plan or that or their family members, but also, more and more often, in shaping entire system reforms. The importance of engaging patients and their organisations in shaping the global healthcare system has a long history.

Patient engagement is usually focused on self-care and sometimes on shared decision making, which means taking responsibility for one's health. However, the debate about the role played by patients at higher levels of the decision-making process has been going on for many years. It is mainly seen through the lens of actions undertaken by individual organisations, which include, among others, popularising knowledge about specific diseases, providing psychological assistance to patients and their families, organising and financially supporting the treatment of patients. Increasing the engagement of patients and their organisations is different from individual engagement and requires strategic action on the part of decision makers.

Therefore, it seems that the responsibility for healthcare outcomes is a joint task for the government, public institutions, healthcare managers, the medical personnel and patients themselves. Their engagement directly impacts various aspects of the broadly understood healthcare functionality. Moving away from traditional paternalistic models, or the role of service providers towards customers, rather than the patients themselves stands in the way of increasing patient engagement and development of value-based healthcare (VBHC). It can take many forms, from improving patient-doctor cooperation and actively listening to patients, through satisfaction surveys, to partnership in decisions based on PROMs (patient reported outcomes measurements), patient experiences or preferences. As part of this session, we wish to present the forms and methods of engaging patients at various levels of system management, together with examples of their contributions to the healthcare development in Poland and worldwide. This session is a continuation of discussions undertaken in the previous years, regarding strengthening the role of patients and their organisations in the system.

Sesja 4. Kto odpowiada za pacjenta w systemie opieki zdrowotnej? Rys. Maciej Dziadyk maciejdziadyk.pl

top

Session 5: Local government academy

The growing role played by local self-governments in the development of healthcare is not limited to legal matters. Some of the tasks imposed on local governments by the Public Health Act of 11 September 2015 include: monitoring and assessing of the community's health condition; health education; health promotion; prevention; activities aimed at eliminating or reducing health risks; activities related to physical activity. Covid-19 brought about additional limitations and problems related to implementation of these tasks. As early as in 2015, local self-governments spent a total of PLN 82.7 million, which means that only the National Health Fund spent more on healthcare. The Medical Fund project indicated the necessity of co-financing preventive programmes, including those organised by local self-governments.

In 2015, the Supreme Audit Office carried out an assessment on the implementation of the tasks of health prevention programmes by local governments; currently this issue is monitored by the National Institute of Public Health – National Institute of Hygiene. However, local governments approach the implementation of tasks related to public health and health prevention programmes very differently. It is estimated that the percentage of local government units implementing health prevention programmes amounts to 25-30% (excluding anti-alcohol and anti-drug programmes, as implementing such programmes by municipalities is a statutory obligation). Of the 21,144 individual tasks, the most frequently undertaken ones were related to prevention, promotion, education and training – the least common ones were related to research. This session will be devoted to discussing the challenges faced by local governments in the new Covid-19 reality, in terms of both health priorities and financial capacities, as well as the practical aspects of implementing health policy programmes.

Sesja 5. Akademia Samorządowca. Rys. Maciej Dziadyk maciejdziadyk.pl

top

Session 6: From data to big data

Healthcare data are an inseparable aspect of progress in health sciences and development of new technologies... The growing awareness of how important these data are and, on the other hand, the need to collect them, already plays a huge role in supporting the stakeholders of the system. New analytical techniques extend their use beyond everyday clinical practice and management of healthcare providers. Additionally, the way they are presented and used is becoming increasingly accessible to the end recipients. Policy-makers and state institutions across the world use these data to make health policy decisions. Nowadays, communication with patients, consists not only in talking to doctors, but also sharing knowledge about the quality and availability of services. Both these measures are the key data of interest to the patients. By using these data, healthcare providers can approach various aspects – clinical, management and financial ones – within a given entity, and use them in hospital-based HTA. Personalisation of medicine or development of VBHC/EBHC are not possible without data analysis, not only from clinical trials, but also from everyday clinical practice, both at the stage of diagnosis and treatment. The aim of knowledge-based systems, including real-world health data, is to implement mechanisms allowing for the most accurate planning and monitoring of care, clinical and economic outcomes, and the quality of care. The dangers concerning data privacy and the security of their collection and processing are discussed not only by analysts, but also by lawyers and ethics experts around the world. During this session, we would like to discuss data sources and the scope of their collection, the possibilities for their use, as well as to discuss practical barriers to accessing them.
Sesja 6. From data to big data. Rys. Maciej Dziadyk maciejdziadyk.pl

top

15. International EBHC Symposium 2020 From Evidence to Action
5-7 października 2021 | ONLINE
15. International EBHC Symposium 2020
From Evidence to Action
5-7 października 2020 | ONLINE

Prezentacje:

  1. Zadania z zakresu zdrowia publicznego realizowane przez JST. Ujęcie ilościowe i jakościowe / PPS 3,7 MB // Aleksandra Czerw, Poland
  2. eZdrowie w Niemczech. Rozważania nad e-zdrowiem z uwzględnieniem nowych przepisów (DVG / DIGAV) i oceny technologii medycznych (HTA) | PDF PDF file – 2,7 MB // Hans-Peter Dauben, Germany
  3. Krajowy Rejestr Nowotworów – szansa dla polskiej onkologii | PDF PDF file – 3,7 MB // Joanna Didkowska, Poland
  4. Zmiana technologii medycznych w praktyce / PPS 1,5 MB // Dominik Dziurda, Poland
  5. Punkty końcowe w hematonkologii – perspektywa kliniczno-systemowa a HTA / PPS 1,5 MB // Krzysztof Giannopoulos , Poland
  6. Realia we wdrażaniu programów polityki zdrowotnej z perspektywy samorządu województwa opolskiego. Wsparcie obszaru zdrowia w ramach RPO WO 2014-2020 / PPS 1,2 MB // Roman Kolek, Poland
  7. Zastępcze punkty końcowe w hematologii – perspektywa systemowa / PPS 0,6 MB // Mariusz Kordecki, Poland
  8. Neurofibromatozy – przykład organizacji opieki koordynowanej w rzadkich chorobach / PPS 3,2 MB // Dorota Korycińska, Poland
  9. SMA – zmiany w zakresie opieki z perspektywy klinicznej / PPS 2,8 MB // Katarzyna Kotulska-Jóźwiak, Poland
  10. Telemonitoring urządzeń wszczepialnych / PPS 8,3 MB // Oskar Kowalski, Poland
  11. Nowoczesna opieka zdrowotna / PPS 9,2 MB // Maciej Krawczyk, Poland
  12. Dane onkologiczne w Polsce – przedstawienie raportu / PPS 6,2 MB // Maria Libura, Poland
  13. HTA w cyfrowym zdrowiu. From data to big data / PPS 0,8 MB // Line H. Linstad, Norway
  14. Wskaźniki jakości w onkologii – wyniki pilotaży sieci onkologicznej | PDF PDF file – 3,3 MB // Adam Maciejczyk, Poland
  15. Wielokryterialna analiza decyzyjna (MCDA, Multi-Criteria Decision Analysis) w ocenie technologii stosowanych w nieonkologicznych chorobach rzadkich / PPS 4 MB // Maciej Niewada, Poland
  16. Projekt ECHO: transfer wiedzy w oparciu o case-based learning i telementoring / PPS 2 MB // James O’Brien, Australia
  17. Dlaczego warto być Zdrowym Miastem? Problemy samorządów w świetle pandemii Covid / PPS 4,5 MB // Maria Piętak-Frączek, Poland
  18. Ocena wyrobów medycznych – wyzwania praktyczne / PPS 2 MB // Robert Plisko, Poland
  19. Grypa – programy polityki zdrowotnej w świetle pandemii / PPS 5,1 MB // Tomasz Prycel, Poland
  20. Szczepienia w systemach ochrony zdrowia – wyzwania / PPS 2 MB // Przemysław Ryś, Poland
  21. Objaśniamy użycie GRADE w ocenie technologii medycznych / PPS 21,2 MB // Holger Schünemann, Canada
  22. Programy polityki zdrowotnej z perspektywy AOTMiT / PPS 2,7 MB // Tomasz Tatara, Poland
  23. Ustalanie priorytetów i strategii – w jaki sposób pacjenci i społeczeństwo uczestniczą w krajowym procesie decyzyjnym / PPS 3,8 MB // Victoria Thomas, UK
  24. Ocena innowacyjności na świecie – podsumowanie rozwiązań międzynarodowych / PPS 2 MB // Magdalena Władysiuk, Poland
  25. HIP – model oceny wpływu na system dla leków stosowanych w wielu wskazaniach / PPS 2,2 MB // Magdalena Władysiuk, Poland
  26. Wyzwania samorządów w świetle pandemii Covid-19 / PPS 0,6 MB // Marek Wójcik, Poland

top

en_GBEnglish (UK)